A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Vor Biopharma
- Study ID
- NCT06456580
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Generalized Myasthenia Gravis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Telitacicept — BIOLOGICALSubcutaneous injection
- Placebo — DRUGSubcutaneous injection
Study Details
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
Key Dates
- First listed
- Jun 13, 2024
- Start date
- Jul 17, 2024
- Status verified
- May 2026
- Primary completion
- May 31, 2027
- Completion
- Jan 31, 2029
Study Design
- Enrollment
- 180 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: TelitaciceptTelitacicept
- Placebo Comparator: PlaceboPlacebo
Primary Outcome Measure
Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24 [ Time Frame: Week 24 ]
Central Contacts
- Jeremy Sokolove617-655-6580
Locations (26)
Find similar trials in Scottsdale, AZ
By research site
HonorHealth Neurology - Bob Bové Neuroscience Institute· Scottsdale, AZUniversity of Southern California· Los Angeles, CAUniversity of California Irvine· Orange, CAUniversity of California San Francisco (UCSF)· San Francisco, CASFM Clinical Research· Boca Raton, FLAllied Biomedical Research Institute (ABRI)· Miami, FL
Related Studies
- Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)Recruiting · Alexion Pharmaceuticals, Inc. · Birmingham, Alabama
- Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisPHASE2/PHASE3 · Recruiting · argenx · Chicago, Illinois
- Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia GravisPHASE2/PHASE3 · Enrolling By Invitation · argenx · Chicago, Illinois
- A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisPHASE2/PHASE3 · Recruiting · UCB Biopharma SRL · Chicago, Illinois